	US 12,251,363 B2
	Compositions to enhance a non-surgical medical treatment
Frank Murdock, Dallas, TX (US); Rodney James Rohrich, Dallas, TX (US); and W. Paul Stewart, Dallas, TX (US)
Assigned to Anti-Plasmin Technologies, LLC, Dallas, TX (US)
Filed by Anti-Plasmin Technologies, LLC, Dallas, TX (US)
Filed on Aug. 12, 2021, as Appl. No. 17/400,895.
Application 17/400,895 is a continuation of application No. 16/576,585, filed on Sep. 19, 2019, granted, now 11,241,405.
Application 16/576,585 is a continuation in part of application No. PCT/US2018/026086, filed on Apr. 4, 2018.
Claims priority of provisional application 62/481,162, filed on Apr. 4, 2017.
Prior Publication US 2021/0369658 A1, Dec. 2, 2021
Int. Cl. A61K 31/195 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/36 (2006.01); A61L 15/44 (2006.01)

CPC A61K 31/195 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 47/36 (2013.01); A61L 15/44 (2013.01)]

23 Claims

1. A non-surgical treatment enhancer comprising:

an antifibrinolytic composition consisting of 15 to 20% (w/v) tranexamic acid and a pharmaceutically acceptable carrier which adapts to human skin,

wherein the enhancer minimizes or reduces swelling, inflammation and bruising associated with the non-surgical treatment.